First AD

Second AD

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.

The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Hepatocellular Carcinoma

Data Updates in GI Cancers and HCC from ESMO 2024

OncLive News Network®

Karmanos Cancer Institute

Cancer Centers

Partner

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

Building Upon Approved Combination Regimens in Unresectable HCC

Ongoing Research in GI Cancers